1365-2710/asset/olbannerleft.jpg?v=1&s=aa84a968ef3e4c88817d0563e21aefa7efa42137)
1365-2710/asset/olbannerright.jpg?v=1&s=a095a2371a8570a4bffe4e80a3cfc0890f8e5615)
The cardioprotective role of β-blockers in patients with diabetes mellitus
Article first published online: 13 AUG 2002
DOI: 10.1046/j.1365-2710.2002.00419.x
1365-2710/asset/cover.gif?v=1&s=27089b9a8052459ae6fd29a17ddd5ca4e94ca963 "Journal of Clinical Pharmacy and Therapeutics")
Additional Information
How to Cite
Landray, M. J., Toescu, V. and Kendall, M. J. (2002), The cardioprotective role of β-blockers in patients with diabetes mellitus. Journal of Clinical Pharmacy and Therapeutics, 27: 233–242. doi: 10.1046/j.1365-2710.2002.00419.x
Publication History
- Issue published online: 13 AUG 2002
- Article first published online: 13 AUG 2002
- Received 1 March 2002, Accepted 2 May 2002
- Abstract
- Article
- References
- Cited By
Keywords:
- β-blocker;
- cardioprotection;
- coronary heart disease;
- diabetes mellitus;
- sudden death
Summary
This paper reviews the role of β-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that β-blockers, in particular the lipophilic agents, substantially reduce cardiovascular mortality and morbidity. However, hitherto β-blockers have been underused in diabetic patients, perhaps because of perceived risks of β-blocker therapy. Reappraisal of the evidence suggests that the traditional reluctance to use β-blockers in this group is based on fears of adverse effects that are largely unfounded.